These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 25090222)

  • 1. Evidence-based decision making in healthcare in Central Eastern Europe.
    Ferrario A; Baltezarević D; Novakovic T; Parker M; Samardzic J
    Expert Rev Pharmacoecon Outcomes Res; 2014 Oct; 14(5):611-5. PubMed ID: 25090222
    [No Abstract]   [Full Text] [Related]  

  • 2. A Pathway Through the Bundle Jungle.
    Polite B; Ward JC; Cox JV; Morton RF; Hennessy J; Page R; Conti RM
    J Oncol Pract; 2016 Jun; 12(6):504-9. PubMed ID: 27173604
    [No Abstract]   [Full Text] [Related]  

  • 3. Who does the numbers? The role of third-party technology assessment to inform health systems' decision-making about the funding of health technologies.
    Barbieri M; Hawkins N; Sculpher M
    Value Health; 2009; 12(2):193-201. PubMed ID: 18700865
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Value of Information Analysis for Research Decisions-An Introduction: Report 1 of the ISPOR Value of Information Analysis Emerging Good Practices Task Force.
    Fenwick E; Steuten L; Knies S; Ghabri S; Basu A; Murray JF; Koffijberg HE; Strong M; Sanders Schmidler GD; Rothery C
    Value Health; 2020 Feb; 23(2):139-150. PubMed ID: 32113617
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Economic evaluation and health care decision-making.
    Rutten F
    Health Policy; 1996 Jun; 36(3):215-29. PubMed ID: 10158267
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Revolution then evolution: the advance of health economic evaluation in Australia.
    Lopert R; Viney R
    Z Evid Fortbild Qual Gesundhwes; 2014; 108(7):360-6. PubMed ID: 25444293
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multiple Criteria Decision Analysis for Health Care Decision Making--Emerging Good Practices: Report 2 of the ISPOR MCDA Emerging Good Practices Task Force.
    Marsh K; IJzerman M; Thokala P; Baltussen R; Boysen M; Kaló Z; Lönngren T; Mussen F; Peacock S; Watkins J; Devlin N;
    Value Health; 2016; 19(2):125-37. PubMed ID: 27021745
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Balancing early access with uncertainties in evidence for drugs authorized by prospective case series - systematic review of reimbursement decisions.
    Wallerstedt SM; Henriksson M
    Br J Clin Pharmacol; 2018 Jun; 84(6):1146-1155. PubMed ID: 29381234
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Health technology assessment and its impact on pharmaceutical pricing and reimbursement policies].
    Castillo-Laborde C; Silva-Illanes N
    Rev Med Chil; 2014 Jan; 142 Suppl 1():S33-8. PubMed ID: 24861178
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Policies for Use of Real-World Data in Health Technology Assessment (HTA): A Comparative Study of Six HTA Agencies.
    Makady A; Ham RT; de Boer A; Hillege H; Klungel O; Goettsch W;
    Value Health; 2017 Apr; 20(4):520-532. PubMed ID: 28407993
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Economic evaluation for pharmaceuticals in Germany.
    Jönsson B
    Eur J Health Econ; 2007 Sep; 8 Suppl 1():S1-2. PubMed ID: 17638033
    [No Abstract]   [Full Text] [Related]  

  • 12. From principle to public policy: using cost-effectiveness analysis.
    Neumann PJ; Johannesson M
    Health Aff (Millwood); 1994; 13(3):206-14. PubMed ID: 7927151
    [No Abstract]   [Full Text] [Related]  

  • 13. How do interventional cardiologists make decisions?: implications for practice and reimbursement.
    Klein LW
    JACC Cardiovasc Interv; 2013 Sep; 6(9):989-91. PubMed ID: 24050872
    [No Abstract]   [Full Text] [Related]  

  • 14. Evolving reimbursement and pricing policies for devices in Europe and the United States should encourage greater value.
    Sorenson C; Drummond M; Burns LR
    Health Aff (Millwood); 2013 Apr; 32(4):788-96. PubMed ID: 23569060
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of a transparent interactive decision interrogator to facilitate the decision-making process in health care.
    Bujkiewicz S; Jones HE; Lai MC; Cooper NJ; Hawkins N; Squires H; Abrams KR; Spiegelhalter DJ; Sutton AJ
    Value Health; 2011; 14(5):768-76. PubMed ID: 21839417
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Decision of the Federal Joint Committee on screening for chorionicity - benefit assessment in the absence of screening studies].
    Schwalm A; Bertelsmann H; Gruber S; Wietschel G; Matthias K
    Gesundheitswesen; 2013 Jan; 75(1):13-21. PubMed ID: 22847814
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The use of non-economic criteria in pricing and reimbursement decisions in Central and Eastern Europe: issues, trends and recommendations.
    Kolasa K; Kalo Z; Zah V
    Expert Rev Pharmacoecon Outcomes Res; 2016 Aug; 16(4):483-8. PubMed ID: 27467881
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of evidence in economic decision models: practical issues and methodological challenges.
    Cooper NJ; Sutton AJ; Ades AE; Paisley S; Jones DR;
    Health Econ; 2007 Dec; 16(12):1277-86. PubMed ID: 18034447
    [TBL] [Abstract][Full Text] [Related]  

  • 19. National Authority for Health: France.
    Rochaix L; Xerri B
    Issue Brief (Commonw Fund); 2009 Jul; 58():1-9. PubMed ID: 19639712
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Decision-analytical modelling in health-care economic evaluations.
    Sun X; Faunce T
    Eur J Health Econ; 2008 Nov; 9(4):313-23. PubMed ID: 17943332
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.